WebOct 22, 2024 · Click Therapeutics, Inc. today announced that it has closed a $52 million upsized Series B financing. Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth ... Web1 day ago · Pear Therapeutics said it would grow from $4 million in 2024 to a whopping $125 million by the end of 2024. It didn’t come close.
Did you know?
WebNov 11, 2024 · NEW YORK, November 11, 2024 -- ( BUSINESS WIRE )-- Click Therapeutics, Inc. ("Click"), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that company ... WebApr 7, 2024 · Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced three corporate governance a
WebApr 15, 2024 · NEW YORK, April 15, 2024 -- ( BUSINESS WIRE )-- Click Therapeutics, Inc. ("Click"), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has secured... WebOct 22, 2024 · October 22, 2024. This morning prescription digital therapeutic company Click Therapeutic announced a $52 million Series B funding round. H.I.G. BioHealth Partners and Accelmed Partners ll led the round, with participation from Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures and …
WebClick Therapeutics is located in New York City, New York. Contact Who is Click Therapeutics Headquarters 80 White St, New York City, New York, 10013, United States Phone Number (646) 248-7933 Website www.clicktherapeutics.com Revenue $9.3M Industry Healthcare Software Software Development & Design Software Click … WebOct 25, 2024 · Post a comment / Oct 25, 2024 at 7:03 PM. Less than a year after its last financing, Click Therapeutics raised $52 million to develop its portfolio of software-based treatments. The New York-based ...
WebIngelheim, Germany and New York, New York, 11 September 2024 – Boehringer Ingelheim and Click Therapeutics today announced they have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic. It will utilize cognitive and neurobehavioral mechanisms delivered through Click’s proprietary …
WebDec 20, 2024 · Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that... lowther dx55WebFounded Date Apr 2012. Founders David Benshoof Klein, Victor Gao. Operating Status Active. Last Funding Type Debt Financing. Legal Name Click Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs ... lowther dx 55WebApr 13, 2024 · NEW YORK, April 13, 2024--(BUSINESS WIRE)--Click Therapeutics, Inc. ("Click"), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief ... jayne mansfield photo galleryWebJan 4, 2024 · Otsuka Pharmaceutical’s US division Otsuka America has partnered with Click Therapeutics to develop and commercialise a prescription digital therapeutic for treating major depressive disorder (MDD). Otsuka and Click intend to offer a new mobile application called CT-152 as a new treatment for major depressive disorder. Credit: … low there do i see my father prayerWebFeb 24, 2024 · Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including Major Depressive Disorder (MDD), Schizophrenia, Acute Coronary Syndrome (ACS), Chronic Pain, Insomnia, Chronic Obstructive Pulmonary Disease (COPD), Obesity, and more. For more information, visit … jayne mansfield photosWebApr 14, 2024 · According to the data, the short interest in Karyopharm Therapeutics Inc. (KPTI) stood at 16.76% of shares outstanding as of Mar 30, 2024; the number of short shares registered in Feb 27, 2024 reached 18.33 million. The stock has risen by 27.06% since the beginning of the year, thereby showing the potential of a further growth. jayne mansfield pics accidentWebDec 19, 2024 · US-based Click Therapeutics has secured breakthrough device designation from the US Food and Drug Administration (FDA) for its CT-132 prescription digital therapeutic candidate as an adjunctive preventive treatment for episodic migraine. Presently under development, CT-132 has been given the designation in patients of age 18 or more. jayne mansfield photos cheesecake